Today: 19 April 2026
Booking Holdings (BKNG) stock slides as visa pause and China probe hit travel shares

Booking Holdings (BKNG) stock slides as visa pause and China probe hit travel shares

New York, January 14, 2026, 20:52 EST — The market has closed.

  • Booking Holdings shares dropped 2.4% Wednesday, marking their third straight day of losses.
  • Shares in travel rivals Expedia and Tripadvisor dipped, with Trip.com’s U.S.-listed ADRs plunging 17%.
  • Traders are eyeing the fallout from shifts in U.S. immigration policy and increased regulatory focus on travel platforms.

Booking Holdings Inc shares slipped 2.4% on Wednesday, closing at $5,187.02. This marked their third day of losses, though they still outperformed some rivals in the travel sector. Expedia Group shares dropped 3.1%, Tripadvisor fell 7.1%, and Trip.com Group’s U.S.-listed ADRs plunged 17.1%.

Selling matters now since travel stocks have become a barometer for policy risk tied to cross-border movement, beyond just consumer demand. Investors also worry regulators might crack down on fees and market dominance at online travel platforms.

Booking finds itself caught in the middle of these forces. It sells hotel nights and other travel services internationally, so changes in consumer mood quickly affect its booking trends and advertising budgets.

China’s market regulator has launched an antitrust probe into Trip.com, citing suspected monopolistic behavior but offering no specifics. Authorities warned that firms violating the anti-monopoly law could be hit with fines ranging from 1% to 10% of their previous year’s revenue. Trip.com confirmed it is cooperating fully.

The Trump administration announced it will halt immigrant visa processing for applicants from 75 countries beginning Jan. 21, as the State Department reviews procedures aimed at blocking potential “public charges” from entering the U.S. A spokesperson clarified that visitor visas remain unaffected—key as the U.S. prepares to host the 2026 World Cup. Reuters

New tourism figures deepened concerns. Despite a 6.7% rise in global tourism spending, the U.S. saw a 6% decline in foreign visitors in 2025, industry data shows. WTTC’s interim chief Gloria Guevara pointed to U.S. anti-immigration policies as a factor driving travelers to Europe and Japan.

Wall Street slipped on Wednesday, dragged down by the Nasdaq as investors sought safety amid mixed big-bank earnings and new economic reports. The broader market offered little support.

Policy headlines pose mixed signals for Booking. The U.S. visa pause focuses on immigrant visas, not tourist travel, and with a global customer base, the company can absorb shocks from one country. Still, stricter screening and additional restrictions could drag down travel overall or hit consumer confidence ahead of the spring booking season.

Thursday’s session will hinge on whether travel stocks find footing after Trip.com’s drop and if new details surface about the U.S. visa pause rollout. The next key date is Jan. 21, when the suspension is set to begin.

Stock Market Today

  • ATI Share Price Surges 262% in One Year, But Valuation Flags Overvaluation
    April 18, 2026, 9:38 PM EDT. Shares of ATI have surged 261.9% over the past year to close at $164.66, fueled by interest in its Aerospace & Defense role. Despite strong gains, ATI scores 0 out of 6 on valuation checks. A Discounted Cash Flow (DCF) model estimates ATI's intrinsic value at approximately $142.92 per share, suggesting the stock is overvalued by 15.2%. The DCF uses projected free cash flows rising from $362.7 million to $1.19 billion by 2035. Investors are questioning whether current prices reflect fundamentals or if sentiment has outpaced growth prospects. Price-to-Earnings (P/E) ratios remain a quick gauge of value, linking share price to current earnings, but must account for growth and risk outlooks. ATI's elevated valuation hints at potential risks despite stellar price momentum.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Critical Metals (CRML) jumps after Greenland drill assays — what to watch next
Previous Story

Critical Metals (CRML) jumps after Greenland drill assays — what to watch next

Qualcomm (QCOM) stock slips as Trump’s AI-chip tariff and RBC’s “no catalysts” call hit the tape
Next Story

Qualcomm (QCOM) stock slips as Trump’s AI-chip tariff and RBC’s “no catalysts” call hit the tape

Go toTop